Lv52
1020 积分 2022-06-07 加入
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
7小时前
待确认
Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD+ Acute Myeloid Leukemia
19小时前
已完结
Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study
25天前
已完结
CT-262: A Randomized Phase 3 Trial in Patients with Hematologic Malignancies Demonstrates Improved Survival Free of Chronic GVHD with Orca-T® Compared to Conventional Allogeneic Hematopoietic Stem Cell Transplant
2个月前
已关闭
Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
2个月前
已完结
Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy
4个月前
已完结
Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer
4个月前
已完结
Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer
4个月前
已完结
AML-454 Real-World Use of Azacitidine (AZA) and Venetoclax (VEN) in Acute Myeloid Leukemia (AML) in Frontline and Relapse/Refractory (R/R) Settings: Multicenter Study From French AURAML Group
4个月前
已完结
Preclinical efficacy of a novel cyclin-dependent kinase 9 inhibitor, QHRD107 against acute myeloid leukemia
4个月前
已完结
皖公网安备34019202002308
